Key result
Therapeutic modulation of ACE2 and Ang-(1-7), including upregulation by statins, may offer potential benefits in pulmonary and extra-pulmonary inflammatory diseases such as COVID-19.
Why the study?
Modulation of Ang-(1-7) offers potential benefit across acute and chronic inflammatory diseases, but the therapeutic role of ACE2 and its modulation required exploration across pulmonary and extrapulmonary conditions, including COVID-19.
Highlights the potential therapeutic benefits of modulating ACE2 and Ang-(1-7) in chronic and acute inflammatory diseases, including COVID-19.
Answers are grounded in this paper and cite their sources.
Supports hypothesis generation for ACE2/Ang-(1-7) modulation in inflammation; leaves open randomized trials before clinical adoption.
Angiotensin Converting Enzyme-2 (ACE2), an important enzyme in the Renin Angiotensin Aldosterone System, degrades Angiotensin II (Ang II) into Angiotensin-(1-7) (Ang-(1-7)), whose actions are opposite to that of Ang II. Interestingly, SARS CoV-2 virus entry into human cells is mediated by ACE2. ACE2 receptors that are widely expressed in lungs and various other organs. Ang-(1-7) seems to have favorable effects on lungs, by preventing fibrosis in lung inflammation models, and exerts a similar action in cardiac and renal pathologies as well. Thus, modulation of Ang-(1-7) can be of potential benefit in chronic as well as acute inflammatory diseases affecting lungs and other organs. Upregulation of ACE2 by statins in different organs, and its consequent beneficial effects, have been demonstrated in many experimental studies, and also in a few clinical ones. This review aims at probing the role of ACE2 and its therapeutic modulation in pulmonary and extra pulmonary diseases, including COVID-19.
No takes yet. Share an insight, caveat, or question.
Magazine et al. (2023) conducted a review in Pulmonary and extra pulmonary diseases, including COVID-19. Modulation of Angiotensin Converting Enzyme-2 (ACE2) and Ang-(1-7) was evaluated. Therapeutic modulation of ACE2 and Ang-(1-7), including upregulation by statins, may offer potential benefits in pulmonary and extra-pulmonary inflammatory diseases such as COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: